References
- Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):1–23.
- He X, Xu CQ. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–669.
- Dömling A, Holak TA. Programmed death-1: therapeutic success after more than 100 years of cancer immunotherapy. Angew Chem Int Ed Engl. 2014;53(9):2286–2288.
- Mould DR, Meibohm B. Drug development of therapeutic monoclonal antibodies. BioDrugs. 2016;30(4):275–293.
- Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563–580.
- Guzik K, Zak KM, Grudnik P, Magiera K, Musielak B, Törner R, Skalniak L, Dömling A, Dubin G, Holak TA, et al. Small-molecule inhibitors of the programmed cell death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1. J Med Chem. 2017;60(13):5857–5867.
- Guzik K, Tomala M, Muszak D, et al. Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief look at progress on small molecules. Peptides and macrocycles. Molecules. 2019;24:2071–2101.
- Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure. 2015;23(12):2341–2348.
- Zhong Y, Li X, Yao H, Lin K. The characteristics of PD-L1 inhibitors, from peptides to small molecules. Molecules. 2019;24(10):1940–1957.
- Spitzer R, Jain AN. Surflex-Dock: Docking benchmarks and real-world application. J Comput Aided Mol Des. 2012;26(6):687–699.
- Wang J, Piotr C, Kollman PA. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules?. J Comput Chem. 2000;21(12):1049–1074.
- Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–2791.
- O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. J Cheminform. 2011;3(1):33–47.
- Case DA, Cheatham TE, III, Darden T, Gohlke H, Luo R, Merz KM, Jr., Onufriev A, Simmerling C, Wang B, Woods RJ, et al. The Amber biomolecular simulation programs. J Comput Chem. 2005;26(16):1668–1688.
- Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA. Development and testing of a general amber force field. J Comput Chem. 2004;25(9):1157–1174.
- Nayar D, Agarwal M, Chakravarty C. Comparison of tetrahedral order, liquid state anomalies, and hydration behavior of mTIP3P and TIP4P water models. J Chem Theory Comput. 2011;7(10):3354–3367.
- Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZH, Hou T. End-point binding free energy calculation with MM/PBSA and MM/GBSA: Strategies and applications in drug design. Chem Rev. 2019;119(16):9478–9508.
- OuYang Y, Gao J, Zhao L, Lu J, Zhong H, Tang H, Jin S, Yue L, Li Y, Guo W, et al. Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo. J Med Chem. 2021;64(11):7646–7666.
- Zhao S-S, Wang Y-J, Tang L, Guo B, Wang L, Zhang J-Q, Yang S-G. Identifying novel selective PPO inhibitors through structure-based virtual screening and bio-evaluation. RSC Adv. 2023;13(16):10873–10883.
- Ali S, Hassan M, Islam A, Ahmad F. A review of methods available to estimate solvent-accessible surface areas of soluble proteins in the folded and unfolded states. CPPS. 2014;15(5):456–476.
- Dong J, Wang N-N, Yao Z-J, Zhang L, Cheng Y, Ouyang D, Lu A-P, Cao D-S. ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. J Cheminform. 2018;10(1):29.